Patents by Inventor WEN-CHENG XIONG
WEN-CHENG XIONG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10877047Abstract: The present invention includes methods for the detection of neurotransmission or developmental disorders, including, but not limited to, myasthenia gravis that is seronegative for autoantibodies to the acetylcholine receptor (AChR) and/or muscle specific tyrosine kinase (MuSK), the method including detecting autoantibodies that bind to LRP4, or an epitope thereof. Also included are methods for the treatment of an individual suffering from a neurotransmission disorder, the method including detecting in a bodily fluid of the individual autoantibodies that bind to LRP4, or an epitope thereof, and administering to the patient an effective amount an immunosuppressant and/or another appropriate therapeutic modality. Also included are antibodies that bind to autoantibodies to LRP4 and kits for the detection of neurotransmission or developmental disorders.Type: GrantFiled: January 29, 2018Date of Patent: December 29, 2020Assignee: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.Inventors: Lin Mei, Wen-Cheng Xiong, Bin Zhang, Chengyong Shen
-
Publication number: 20180231572Abstract: The present invention includes methods for the detection of neurotransmission or developmental disorders, including, but not limited to, myasthenia gravis that is seronegative for autoantibodies to the acetylcholine receptor (AChR) and/or muscle specific tyrosine kinase (MuSK), the method including detecting autoantibodies that bind to LRP4, or an epitope thereof. Also included are methods for the treatment of an individual suffering from a neurotransmission disorder, the method including detecting in a bodily fluid of the individual autoantibodies that bind to LRP4, or an epitope thereof, and administering to the patient an effective amount an immunosuppressant and/or another appropriate therapeutic modality. Also included are antibodies that bind to autoantibodies to LRP4 and kits for the detection of neurotransmission or developmental disorders.Type: ApplicationFiled: January 29, 2018Publication date: August 16, 2018Applicant: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.Inventors: Lin Mei, Wen-Cheng Xiong, Bin Zhang, Chengyong Shen
-
Patent number: 9897614Abstract: The present invention includes methods for the detection of neurotransmission or developmental disorders, including, but not limited to, myasthenia gravis that is seronegative for autoantibodies to the acetylcholine receptor (AChR) and/or muscle specific tyrosine kinase (MuSK), the method including detecting autoantibodies that bind to LRP4, or an epitope thereof. Also included are methods for the treatment of an individual suffering from a neurotransmission disorder, the method including detecting in a bodily fluid of the individual autoantibodies that bind to LRP4, or an epitope thereof, and administering to the patient an effective amount an immunosuppressant and/or another appropriate therapeutic modality. Also included are antibodies that bind to autoantibodies to LRP4 and kits for the detection of neurotransmission or developmental disorders.Type: GrantFiled: December 11, 2015Date of Patent: February 20, 2018Assignee: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.Inventors: Lin Mei, Wen-Cheng Xiong, Bin Zhang, Chengyong Shen
-
Patent number: 9493542Abstract: Compositions that inhibit or block the interaction between Erbin and ErbB2 and methods of their use are provided. Preferred compositions include peptides that inhibit or block Erbin and ErbB2 interaction under physiologic conditions in a subject. One embodiment provides an isolated peptide fragment of ErbB2 including the C-terminal 15 amino acids of ErbB2. The peptide fragment can be about 15 to 27 amino acids in length.Type: GrantFiled: February 24, 2014Date of Patent: November 15, 2016Assignee: Augusta University Research Institute, Inc.Inventors: Lin Mei, Wen-Cheng Xiong, Cheng-Yong Shen, Yan-Mei Tao, Shi-Wen Luo
-
Publication number: 20160187355Abstract: The present invention includes methods for the detection of neurotransmission or developmental disorders, including, but not limited to, myasthenia gravis that is seronegative for autoantibodies to the acetylcholine receptor (AChR) and/or muscle specific tyrosine kinase (MuSK), the method including detecting autoantibodies that bind to LRP4, or an epitope thereof. Also included are methods for the treatment of an individual suffering from a neurotransmission disorder, the method including detecting in a bodily fluid of the individual autoantibodies that bind to LRP4, or an epitope thereof, and administering to the patient an effective amount an immunosuppressant and/or another appropriate therapeutic modality. Also included are antibodies that bind to autoantibodies to LRP4 and kits for the detection of neurotransmission or developmental disorders.Type: ApplicationFiled: December 11, 2015Publication date: June 30, 2016Inventors: Lin Mei, Wen-Cheng Xiong, Bin Zhang, Chengyong Shen
-
Patent number: 9244082Abstract: The present invention includes methods for the detection of neurotransmission or developmental disorders, including, but not limited to, myasthenia gravis that is seronegative for autoantibodies to the acetylcholine receptor (AChR) and/or muscle specific tyrosine kinase (MuSK), the method including detecting autoantibodies that bind to LRP4, or an epitope thereof. Also included are methods for the treatment of an individual suffering from a neurotransmission disorder, the method including detecting in a bodily fluid of the individual autoantibodies that bind to LRP4, or an epitope thereof, and administering to the patient an effective amount an immunosuppressant and/or another appropriate therapeutic modality. Also included are antibodies that bind to autoantibodies to LRP4 and kits for the detection of neurotransmission or developmental disorders.Type: GrantFiled: April 20, 2012Date of Patent: January 26, 2016Assignee: Georgia Regents Research Institute, Inc.Inventors: Lin Mei, Wen-Cheng Xiong, Bin Zhang, Chengyong Shen
-
Publication number: 20140243268Abstract: Compositions that inhibit or block the interaction between Erbin and ErbB2 and methods of their use are provided. Preferred compositions include peptides that inhibit or block Erbin and ErbB2 interaction under physiologic conditions in a subject. One embodiment provides an isolated peptide fragment of ErbB2 including the C-terminal 15 amino acids of ErbB2. The peptide fragment can be about 15 to 27 amino acids in length.Type: ApplicationFiled: February 24, 2014Publication date: August 28, 2014Applicant: Georgia Regents Research Institute, Inc.Inventors: Lin Mei, Wen-Cheng Xiong, Cheng-Yong Shen, Yan-Mei Tao, Shi-Wen Luo
-
Patent number: 8524228Abstract: Methods and compositions for male or female contraception are provided. The compositions include an effective amount of netrin-1 to reduce or inhibit sperm concentration in semen of males or to inhibit or reduce fusion of male gametes with female gametes in a female subject Still another embodiment provides a method for diagnosing male infertility by determining the amount of netrin-1 in a sample of epididymal fluid or semen from a male subject, comparing the amount of netting-1 in the sample to levels of netrin-1 in samples of epididymal fluid or semen from fertile males, wherein levels of netrin-1 in the sample from the male subject that are higher or lower than levels of netrin-1 in samples from fertile males are indicative of male infertility in the male subject.Type: GrantFiled: November 3, 2008Date of Patent: September 3, 2013Assignee: Medical College of Georgia Research Institute, Inc.Inventors: Wen-Cheng Xiong, Jae-Ho Lee, Lin Mei
-
Publication number: 20130108616Abstract: The present invention includes methods for the detection of neurotransmission or developmental disorders, including, but not limited to, myasthenia gravis that is seronegative for autoantibodies to the acetylcholine receptor (AChR) and/or muscle specific tyrosine kinase (MuSK), the method including detecting autoantibodies that bind to LRP4, or an epitope thereof. Also included are methods for the treatment of an individual suffering from a neurotransmission disorder, the method including detecting in a bodily fluid of the individual autoantibodies that bind to LRP4, or an epitope thereof, and administering to the patient an effective amount an immunosuppressant and/or another appropriate therapeutic modality. Also included are antibodies that bind to autoantibodies to LRP4 and kits for the detection of neurotransmission or developmental disorders.Type: ApplicationFiled: April 20, 2012Publication date: May 2, 2013Inventors: Lin Mei, Wen-Cheng Xiong, Bin Zhang, Changyong Shen
-
Publication number: 20120039881Abstract: Methods and compositions for modulating GABA release in a subject are provided. A preferred embodiment provides a composition containing an effective amount of an ErbB4 ligand to enhance or promote GABA release, i.e., GABAergic transmission. The ErbB4 ligand can be an agonist ligand or an antagonist ligand depending on the disorder to be treated. Methods for treating neurological disorders are also provided. Representative disorders that can be treated include, but are not limited to schizophrenia, epilepsy, depression and anxiety, insomnia, stroke, pain, bipolar, autism, or a combination thereof. By increasing GABA release a sedative effective can be induced in the subject. Methods for inducing a stimulatory effect in a subject are also provided. In these methods, an effective amount of an ErbB4 antagonist ligand is administered to the subject to reduce or inhibit GABA release in the subject.Type: ApplicationFiled: October 21, 2011Publication date: February 16, 2012Inventors: Lin Mei, Wen-Cheng Xiong, Ran-Sook Woo, Xiaoming Li
-
Publication number: 20100260774Abstract: Methods and compositions for male or female contraception are provided. The compositions include an effective amount of netrin-1 to reduce or inhibit sperm concentration in semen of males or to inhibit or reduce fusion of male gametes with female gametes in a female subject Still another embodiment provides a method for diagnosing male infertility by determining the amount of netrin-1 in a sample of epididymal fluid or semen from a male subject, comparing the amount of netting-1 in the sample to levels of netrin-1 in samples of epididymal fluid or semen from fertile males, wherein levels of netrin-1 in the sample from the male subject that are higher or lower than levels of netrin-1 in samples from fertile males are indicative of male infertility in the male subject.Type: ApplicationFiled: November 3, 2008Publication date: October 14, 2010Applicant: MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INCInventors: Wen-Cheng Xiong, Jae-Ho Lee, Lin Mei
-
Publication number: 20100136004Abstract: Methods and compositions for modulating GABA release in a subject are provided. A preferred embodiment provides a composition containing an effective amount of an ErbB4 ligand to enhance or promote GABA release, i.e., GABAergic transmission. The ErbB4 ligand can be an agonist ligand or an antagonist ligand depending on the disorder to be treated. Methods for treating neurological disorders are also provided. Representative disorders that can be treated include, but are not limited to schizophrenia, epilepsy, depression and anxiety, insomnia, stroke, pain, bipolar, autism, or a combination thereof. By increasing GABA release a sedative effective can be induced in the subject. Methods for inducing a stimulatory effect in a subject are also provided. In these methods, an effective amount of an ErbB4 antagonist ligand is administered to the subject to reduce or inhibit GABA release in the subject.Type: ApplicationFiled: November 23, 2009Publication date: June 3, 2010Inventors: LIN MEI, WEN-CHENG XIONG, RAN-SOOK WOO, XIAOMING LI